Endocrine Abstracts

Somatostatin acts as an inhibitor of hormonal secretion and cell proliferation by acting through 5 somatostatin receptors subtypes (sst1–5). Coupling with Gi/o proteins is associated with effects on various transduction pathways, as adenylate cyclase inhibition or phosphatases activation. Dopamine receptor subtype 2 (D2DR) acts through coupling with similar G-proteins and transduction pathways. Sst, mostly sst2 and sst5, are coexpressed with D2DR in many neuroendocrine no...

Objective: We describe two first cousins presenting with neonatal corticotropic deficiency and severe, early-onset obesity. This study aims to identify the molecular etiology of these disorders in both cases and highlights the limits of genetic investigations.Methods: We collected the clinical-biological data of the family and, more particularly, of the two first cousins (A and B). We performed several constitutive Next-generation Sequencing (NGS) protoc...

Somatotroph adenoma represent 20% of pituitary adenoma. Although often considered as benign, they can induce serious neurological and metabolic complications. GH hypersecretion can be inhibited by somatostatin agonists such as octreotide or lanreotide. However, some GH levels reach normal values in only 50% of treated patiens. The decreased sensitivity to the somatostatin agonists was shown to be related to a lower expression of the sst2 gene.To reverse ...